On November 27, 2024, a research team led by Professor Qiu Fuming from the Second Affiliated Hospital of Zhejiang University School of Medicine published a case report titled "Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer" in the oncology-focused journal Frontiers in Oncology.

On November 2, 2024, according to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, Escugen's core product ESG401 (recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate) was granted Breakthrough Therapy Designation (BTD).